查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1592120

白血病藥物市場：按類型、按治療類型、按分子類型、按劑型、按性別 - 2025-2030 年全球預測

Leukemia Therapeutics Market by Type, Treatment Type, Molecule Type, Mode of Administration, Gender - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年白血病藥物市值為156.4億美元，預計到2024年將達到167.3億美元，複合年成長率為7.02%，到2030年將達到251.7億美元。

白血病藥物的範圍包括旨在管理和潛在治癒各種類型白血病的醫療干預和治療，包括急性淋巴細胞白血病、急性骨髓性白血病、慢性淋巴性白血病和慢性骨髓性白血病的治療。這些治療方法包括化療、免疫療法、標靶治療和骨髓移植。全球白血病的高負擔以及對有效治療方案的需求以改善患者的治療結果和存活率推動了對白血病藥物的需求。該調查針對廣泛的研究機構、醫療機構和製藥公司，重點關注腫瘤學專業人士、研究人員和患者。最終用途範圍包括實施這些治療的醫院、癌症研究機構和專科診所。根據市場洞察，關鍵的成長要素包括個人化醫療和標靶治療的進步、研究經費的增加以及全球盛行率的提高。 CAR T 細胞療法和其他創新免疫療法的出現代表著一個重大機遇，因為它們有望提供更精確、更有效的治療選擇。低毒性、高標靶性的小分子抑制劑的開發也有很大潛力，使我們在市場競爭中具有優勢。然而，限制因素包括高昂的治療成本、複雜的監管核准以及與目前治療相關的潛在副作用，這些都限制了市場的成長。此外，白血病診斷，特別是在早期階段，提出了獨特的挑戰，這進一步使市場擴張變得複雜。創新和研究的最佳領域包括探索藥物開發的新機制目標、增強現有治療的傳遞機制以及完善基因和生物標記分析以個性化治療通訊協定。市場具有創新快、競爭激烈的特點，需要相關人員不斷創新和合作才能保持競爭力。市場上的成功參與者應專注於與研究機構的合作、研發投資以及適應性策略，以應對永續成長的監管挑戰。

主要市場統計
基準年[2023] 156.4億美元
預測年份 [2024] 167.3億美元
預測年份 [2030] 251.7億美元
複合年成長率（%） 7.02%

市場動態：揭示快速發展的白血病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變白血病藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 白血病患者增加
    • 癌症治療的需求不斷成長
    • 加大醫療健康領域投資
  • 市場限制因素
    • 治療成本上升和新治療藥物的開發
  • 市場機會
    • 為白血病患者開發創新的診斷和治療藥物
    • 增加對醫療保健產業的投資和有利的政府舉措
  • 市場挑戰
    • 嚴格監管場景

波特五力：駕馭白血病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對白血病藥物市場的影響

外部宏觀環境因素在塑造白血病藥物市場的表現動態中起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解白血病治療藥物市場的競爭狀況

白血病治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣白血病藥物市場供應商的績效評估

FPNV 定位矩陣是評估白血病藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製白血病藥物市場的成功之路

白血病藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 白血病發生率上升
      • 癌症治療的需求不斷增加
      • 加大醫療健康領域投入
    • 抑制因素
      • 治療成本上升和新治療方法的開發
    • 機會
      • 為白血病患者開發創新的診斷和治療方法
      • 增加對醫療保健產業的投資和有利的政府舉措
    • 任務
      • 嚴格監管場景
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章白血病藥物市場：按類型

  • 急性淋巴性白血病
  • 急性骨髓性白血病
  • 慢性淋巴性白血病
  • 慢性骨髓性白血病

第7章依治療類型分類的白血病治療藥物市場

  • 化療
  • 標靶藥物和免疫治療

第8章按分子類型分類的白血病藥物市場

  • 生物製藥
  • 小分子

第9章 依管理方式分類的白血病治療藥物市場

  • 注射方式
  • 口語模式

第10章白血病治療藥物市場性別

  • 女士
  • 男人

第11章 北美、南美白血病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區白血病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲白血病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • AstraZeneca PLC
  • Biogen Inc
  • Bristol Myers Squibb Company
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corp
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-4342CA3265BE

The Leukemia Therapeutics Market was valued at USD 15.64 billion in 2023, expected to reach USD 16.73 billion in 2024, and is projected to grow at a CAGR of 7.02%, to USD 25.17 billion by 2030.

The scope of leukemia therapeutics encompasses the range of medical interventions and treatments aimed at managing and potentially curing various types of leukemia, including acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia. These therapies include chemotherapy, immunotherapy, targeted therapy, and bone marrow transplants. The necessity of leukemia therapeutics arises from the high global burden of leukemia, which necessitates effective therapeutic options to improve patient outcomes and survival rates. Applications are broad, involving research laboratories, healthcare institutions, and pharmaceutical companies, catering primarily to oncology specialists, researchers, and patients. End-use scopes include hospitals, cancer research institutes, and specialty clinics that administer these therapies. Market insights reveal that key growth factors include advancements in personalized medicine and targeted therapies, rising research funding, and increasing prevalence rates worldwide. A significant opportunity arises with the advent of CAR T-cell therapies and other innovative immunotherapies that promise more precise and effective treatment options. There is also significant potential in developing less toxic and more targeted small molecule inhibitors, which can provide competitive market advantages. However, limitations include the high cost of treatment, complex regulatory approvals, and potential side effects associated with current therapies, which restrain market growth. Moreover, the inherent challenges in diagnosing leukemia, particularly in its early stages, further complicate market expansion. The best areas for innovation and research include exploring new mechanistic targets for drug development, enhancing delivery mechanisms for existing treatments, and refining genetic and biomarker profiling to personalize therapy protocols. The market is characterized by rapid technological advancements and high competition, necessitating continuous innovation and collaboration among stakeholders to maintain a competitive edge. Successful market players should focus on collaborative efforts with research institutions, investment in R&D, and adaptive strategies to address regulatory challenges for sustained growth.

KEY MARKET STATISTICS
Base Year [2023] USD 15.64 billion
Estimated Year [2024] USD 16.73 billion
Forecast Year [2030] USD 25.17 billion
CAGR (%) 7.02%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Leukemia Therapeutics Market

The Leukemia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of leukemia cases
    • Growing need for cancer therapy
    • Increasing investment in healthcare sector
  • Market Restraints
    • High cost of treatment and development of new therapeutics
  • Market Opportunities
    • Development of innovative diagnostic and therapeutics for leukemia patients
    • Expanding investments in the healthcare sector and favorable government initiatives
  • Market Challenges
    • Stringent regulatory scenario

Porter's Five Forces: A Strategic Tool for Navigating the Leukemia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Leukemia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Leukemia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Leukemia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Leukemia Therapeutics Market

A detailed market share analysis in the Leukemia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Leukemia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Leukemia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Leukemia Therapeutics Market

A strategic analysis of the Leukemia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Leukemia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, Biogen Inc, Bristol Myers Squibb Company, Eisai Co., Ltd, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corp, Johnson & Johnson Services, Inc., Merck KGaA, Novartis International AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Leukemia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia.
  • Based on Treatment Type, market is studied across Chemotherapy and Targeted Drugs & Immunotherapy.
  • Based on Molecule Type, market is studied across Biologics and Small Molecules.
  • Based on Mode of Administration, market is studied across Injectable Mode and Oral Mode.
  • Based on Gender, market is studied across Female and Male.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of leukemia cases
      • 5.1.1.2. Growing need for cancer therapy
      • 5.1.1.3. Increasing investment in healthcare sector
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment and development of new therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of innovative diagnostic and therapeutics for leukemia patients
      • 5.1.3.2. Expanding investments in the healthcare sector and favorable government initiatives
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory scenario
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Leukemia Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Acute Lymphocytic Leukemia
  • 6.3. Acute Myeloid Leukemia
  • 6.4. Chronic Lymphocytic Leukemia
  • 6.5. Chronic Myeloid Leukemia

7. Leukemia Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Targeted Drugs & Immunotherapy

8. Leukemia Therapeutics Market, by Molecule Type

  • 8.1. Introduction
  • 8.2. Biologics
  • 8.3. Small Molecules

9. Leukemia Therapeutics Market, by Mode of Administration

  • 9.1. Introduction
  • 9.2. Injectable Mode
  • 9.3. Oral Mode

10. Leukemia Therapeutics Market, by Gender

  • 10.1. Introduction
  • 10.2. Female
  • 10.3. Male

11. Americas Leukemia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Leukemia Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Leukemia Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AstraZeneca PLC
  • 3. Biogen Inc
  • 4. Bristol Myers Squibb Company
  • 5. Eisai Co., Ltd
  • 6. F. Hoffmann-La Roche AG
  • 7. Gilead Sciences, Inc.
  • 8. GlaxoSmithKline PLC
  • 9. Incyte Corp
  • 10. Johnson & Johnson Services, Inc.
  • 11. Merck KGaA
  • 12. Novartis International AG
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. LEUKEMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LEUKEMIA THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED DRUGS & IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MODE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY ORAL MODE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM LEUKEMIA THERAPEUTICS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
  • TABLE 233. LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023